Ana Anderson

Ana Anderson

Associate Professor of Neurology
Ana Anderson

Research in the Anderson Laboratory focuses on understanding the pathways and mechanisms that regulate the T cell response in chronic disease, particularly in cancer. Specific areas of investigation are examination of the role of co-inhibitory/immune checkpoint receptor pathways in regulating effector and regulatory T cells (Treg) in cancer and defining the distinct effector T cell states present in tumor tissue.

Co-inhibitory/immune checkpoint receptors are a class of cell surface receptors that are up-regulated on activated T cells in order to contract pro-inflammatory T cell responses, thus precluding the unwanted consequences of uncontrolled inflammation. Unfortunately, co-inhibitory receptors have been co-opted in cancer such that their constitutive and high expression on T cells in tumor tissue dampens anti-tumor T cell responses. The Anderson lab has done pioneering research on the role of the co-inhibitory receptor Tim-3 in regulating anti-tumor immunity. Current research focuses on dissecting the role of Tim-3 and other co-inhibitory receptors in the regulation of different immune cell subsets in tumor tissue and elucidating how blockade of Tim-3 signaling alters the function of immune cell subsets in the tumor microenvironment.

CD8+ cytotoxic T cells are key to successful anti-tumor immunity. However, CD8+ T cells loose their functional efficacy in tumor tissue. A major research effort in the Anderson lab is to molecularly dissect the dysfunctional T cell state in cancer using transcriptomics and systems biology approaches.

CD4+FoxP3+ Treg are major suppressors of anti-tumor immunity. The Treg cells that infiltrate tumor tissue up-regulate immune checkpoint receptors and exhibit a highly active and suppressive phenotype. A major research effort in the Anderson lab is to elucidate how checkpoint receptor pathways direct the function of Treg in tumor tissue.

Integrated into the above research efforts are the use of cutting-edge technologies such as CyTOF, single-cell transcriptomics, and genome-editing approaches. We have developed a custom mass cytometry platform to assess the landscape of co-stimulatory and co-inhibitory receptors in tumor tissue using CyTOF. In collaboration with investigators at the Broad Institute, we are using single-cell transcriptomics and systems biology approaches to unravel the molecular programs associated with dysfunctional CD8+ T cells and highly active Treg in cancer. We are further taking advantage of recent advances in genome-editing using CRISPR/Cas9 to elucidate how key molecular targets affect the anti-tumor T cell response.

Contact Information

Brigham and Women's Hospital
Evergrande Center for Immunologic Diseases
60 Fenwood Road, BTM 10016G
Boston, MA 02115
p: 617-525-5850